Antengene to Present Three Program Results at 2024 SITC Annual Meeting

Antengene Corporation Limited, a prominent global biopharmaceutical enterprise, has announced its participation in the 2024 Society of Immunology in Cancer Annual Meeting (SITC 2024), which will take place in Houston from November 6-10, 2024. The company will present three significant research programs during the event.

The first program involves ATG-201, a novel "2+1" CD19-targeted T-cell Engager (TCE) designed for the treatment of B-cell malignancies and B-cell-related autoimmune diseases. The presentation, titled "ATG-201, a novel '2+1' CD19-targeted T-cell Engager (TCE) for the treatment of B-cell malignancies and B-cell related autoimmune diseases," will be showcased twice. It will first feature at the SITC Immune Engineering Workshop on November 7, 2024, from 3:10 PM to 5:00 PM Central Standard Time (CST) and again at the SITC 39th Annual Meeting on November 8, 2024, from 9:00 AM to 7:00 PM CST.

The second program centers on ATG-107, another innovative "2+1" CD3-based T-cell Engager targeting FLT3. This program, aimed at treating acute myeloid leukemia (AML), is presented under the title "ATG-107, a novel '2+1' CD3-based T-cell Engager targeting FLT3, demonstrates potent preclinical efficacy for the treatment of AML." The presentation schedule includes the SITC Immune Engineering Workshop on November 7, 2024, from 3:10 PM to 5:00 PM CST, followed by a poster presentation at the SITC 39th Annual Meeting on November 9, 2024, from 9:00 AM to 8:30 PM CST.

The third research program features ATG-106, a "2+1" format CDH6-targeted T-cell Engager, which exhibits substantial T-cell-dependent cytotoxicity and in vivo anti-tumor efficacy. This program will be presented at the SITC 39th Annual Meeting on November 8, 2024, from 9:00 AM to 7:00 PM CST. The presentation is titled "ATG-106, a novel '2+1' format CDH6-targeted T-cell Engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacy."

Antengene's proprietary AnTenGager™ Platform, a "2+1" T-cell engager (TCE) system, forms the basis of these innovative programs. This platform enables simultaneous binding to disease-associated antigens and a unique epitope on CD3 expressed on T-cells. The dual binding mechanism ensures the detection and elimination of cells with low antigen expression and activates T-cells in a target-dependent manner. This reduces the risk of systemic CD3 activation and cytokine release syndrome (CRS), making these TCEs potentially applicable in autoimmune diseases, hematological malignancies, and solid tumors.

The extensive pipeline at Antengene includes promising TCEs addressing unmet medical needs in autoimmune diseases and oncology. Some notable programs are ATG-201 for B-cell-related autoimmune diseases, ATG-102 targeting acute myeloid leukemia and chronic myelomonocytic leukemia, ATG-106 for ovarian and kidney cancers, ATG-107 for AML, and ATG-110 aimed at microsatellite stable colorectal cancer.

Antengene Corporation Limited, established in 2017, is recognized for its focus on discovering, developing, and commercializing innovative therapies for hematologic malignancies and solid tumors. The company has developed a comprehensive pipeline of nine oncology assets at various stages, including six with global rights and three with rights for the APAC region. Antengene has secured 29 investigational new drug (IND) approvals in the U.S. and Asia and has submitted ten new drug applications (NDAs) across multiple Asia-Pacific markets. Notably, their NDA for XPOVIO® (selinexor) has already been approved in several regions, including Mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, Malaysia, Thailand, and Australia.